Previous close | 1.5200 |
Open | 1.5300 |
Bid | 1.6500 x 600 |
Ask | 1.6800 x 400 |
Day's range | 1.5300 - 1.7000 |
52-week range | 0.6200 - 2.3100 |
Volume | |
Avg. volume | 1,760,974 |
Market cap | 208.005M |
Beta (5Y monthly) | 1.24 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The expanded research agreement with Weill Cornel
SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines i
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical st